Omega-3-Carboxylic Acids

Chicago, IL, April 09, 2021 (GLOBE NEWSWIRE) -- Vitaae is an advanced anti-aging nootropic product meant to improve mental cognition through its’ potent blend of clinically studied ingredients. Manufactured by SANE Labs, Vitaae is one of the safest and most effective nootropic compounds for enhancing memory, focus, learning, and overall cognition. If you’re a student, an entrepreneur, or just someone who feels like they lost your mental edge, then Vitaae may be the perfect anti-aging clinical research nootropic formulation for you. The opening review for the Vitaae product page is relatively simple. Chris P. asks if readers have ever gone into a room and forgotten why. If they have, he says that Vitaae might be for them. After all, the supplement may have improved Chris’ memory issues. The Vitaae supplement specially formulated to help people improve brain utilization, as well as “membrane turnover.” The creators of Vitaae say that their formula can help to maximize “mental clarity, deeper concentration, and better moods.” Perhaps most importantly, the supplement is purportedly capable of protecting “your most precious memories.” The creators behind Vitaae blame many brain problems on something known as “leaky brain.” According to the official product website, a leaky brain contributes to a slower metabolism, brain fog, and lower energy. People struggling with leaky brains might even experience anxiety, depression, and mood swings. These are serious issues. We’d like to emphasize that people who have serious symptoms like depression, memory loss, and anxiety should consult their physician immediately. Supplementation is often a wise strategy to deal with these problems, but there is truly no substitute for a genuine evaluation by medical professionals. It is impossible to evaluate any supplement without closely examining its core ingredients. The official website for SANE Vitaae clearly understands this important point; the product page explains that the formula is “clinically proven” to boost brain power and boost memory function. The key study cited on the product page is the “brain boosting fountain of youth” study, which found a few surprising things about the main ingredient used in Vitaae. Notably, the study found that using this ingredient resulted in a 90% decrease in “focus errors,” a 13.6% “increase in brain energy utilization,” and a 26% increase in “membrane turnover.” The membrane turnover is a literal “reversal of aging of your brain.” Are you interested in trying Vitaae? There’s nothing more upsetting than slowly losing your memory, especially as you age. Serious problems with the brain should be addressed in a genuine medical setting. However, we do have reason to believe that some supplements, including Vitaae, may help to boost memory and brain power. Read on to learn all the key pieces of evidence about Vitaae. What is Vitaae & How Does it Work? SANE Vitaae is considered a “nootropic” supplement, sometimes referred to as “smart drugs.” However, there’s no prescription needed to take Vitaae, and it is completely safe using only natural, clinically studied ingredients. The well-respected SANE Laboratories manufacture Vitaae. Their CEO, Johnathan Bailor, is a best-selling author, award-winning movie producer, and owner of 26 patents related to health and wellness. His work is even endorsed by doctors from the Harvard Medical School, John Hopkins, and Cleveland Clinic. Through his extensive research, Bailor developed Vitaae to combat poor cognition and various products in the SANE Labs production line. So how exactly does Vitaae work? Vitaae reduces inflammation in the brain, which slows down neural connections: A lot of your brain fog, poor concentration, and other cognitive decline types can be traced back to inflammation in the brain. Essentially, neurological (brain) inflammation slows down how fast the brain's neurons can fire and make connections. This causes our normal cognitive functions like memory, focus, and learning to slow down. Unfortunately, many brain inflammation found in adults can be directly linked to the natural aging process. As we age, our immune system weakens, making us more susceptible to inflammation and damage in our bodies. Thankfully, Vitaae may help eliminate the brain's inflammation, enabling the brain's neurons to fire as quickly as they previously could when healthy. Besides, according to the SANE formulators, Vitaae helps protect the brain from future damage and inflammation by enhancing immunity. Vitaae provides a boost in brain energy so the brain can operate more efficiently: Vitaae contains citicoline and CoQ10 – two ingredients that help stimulate “brain energy utilization” and sparks energy within the cells. In other words, both of these ingredients boost your energy levels and allow your brain to function better by supplying it with the energy source it needs. Ingredients in Vitaae Like all of the products made by SANE labs, Vitaae uses clinically studied ingredients to restore healthy cognition and boost your energy levels. In total, there are five ingredients in Vitaae, all of which are proven to support healthy cognition and overall health in various ways. These five ingredients are: MagnaFolate C®: MagnaFolate C® is a patented form of folate that is more bioavailable (easily absorbed) by the body. Studies have found folic acid is crucial in DNA synthesis and protein synthesis. Low levels of folic acid can make the body more susceptible to illness and disease, and supplying the body with folic acid improves neural health and reduces inflammation-causing poor cognition. Vitamin D: Vitamin D is an essential vitamin needed for neurodevelopment and proper brain function. Studies have found low vitamin D levels can cause poor cognition and lead to sickness and inflammation because of a weakened immune system. Cognazin™ - Cognazin is a patented form of citicoline (a naturally occurring chemical in the body) that has been clinically studied and proven to support memory recall and brain function. It also has strong neuroprotective properties and supports cellular synthesis, brain energy levels, and concentration. VitaalMind Proprietary Blend™ - The VitaalMind Blend contains omega 3 fatty acids, reducing inflammation and protecting the brain from future inflammation. SANE Labs also claims this blend has “the potential to help people with mood disorders” and quotes a Harvard Medical School study. CoQ10 – CoQ10 is “the essential brain nutrient” that helps supply the body with energy, boosts your immunity, and provides antioxidant functions for the body. Vitaae uses a patented form of CoQ10 to boost bioavailability further so that you can feel the benefits even faster. Benefits of Vitaae Vitaae is one of the most revolutionary nootropic supplements on the market because it uses clinically studied ingredients. It is why tens of thousands of people rely on it every day to support their cognition and stop brain aging. Within weeks, you can experience these same benefits by taking Vitaae: Improved memory recall: Memory recall requires that the neurons in the brain fire as quickly as possible. This process can be slowed or even stopped completely because of brain inflammation, which causes poor memory and forgetfulness. Vitaae uses several ingredients to help support faster neural connections to improve your memory recall. Better focus & energy: CoQ10 and Cognazin help feed the brain with essential nutrients that supply the brain with plenty of energy. This helps support your focus, concentration, and overall productiveness throughout the entire day. This is why college students and business professionals find Vitaae so impressive and useful. Better mood: Choline and Vitamin D are linked to a better mood because they help release pleasure chemicals in the brain like dopamine and serotonin. Vitamin D is beneficial because low vitamin D levels have been directly linked to depression, which is why many Vitaae users with depression have found the product to be a nice alternative to antidepressants. Is Vitaae Safe? What are the Side Effects of Vitaae? What separates Vitaae from other popular nootropic compounds is that not only is it effective – it is safe too. All of the ingredients in Vitaae have been thoroughly vetted through clinical research and are proven to be safe for both short-term and long-term use. In general, there are no side effects while taking Vitaae. Some users may experience a slight headache or nausea while taking Vitaae, but these side effects are rare and mild. In general, any supplement can cause these side effects, and they are not exclusive to Vitaae. SANE Labs also has a history of manufacturing safe, clean supplements free from stimulants, fillers, artificial ingredients, or dangerous chemicals. Their commitment to safety is unparalleled in the supplement industry, which is why you can rest easy knowing Vitaae is made with the best quality & safest ingredients. If you still feel like Vitaae may not be safe for you, consult your doctor or a medical professional before trying the product. He or she should guide you and tell you whether this product is safe for you to take. How Long Does Vitaae to See Results? Vitaae has proven ingredients that can and will boost your cognition with continual use. However, Vitaae is not a miracle product that can deliver mind-blowing results overnight. It would be best if you gave the product some time to work before you make any judgment. The manufacturer recommends you give the product a full 30 to 60 days before you make any judgment on whether the product is working for you. However, according to customer testimonials, many users saw results in as little as a few weeks. As they continued to use the product, they gradually saw more improvements each week. We recommend that you listen to SANE Labs and take the product for at least 30 to 60 days before you make any judgment on whether or not it works. For the best results, 60 days is probably the best timeframe to measure any changes you may be experiencing. Is Vitaae a Scam? Although Vitaae is largely considered one of the best nootropic compounds on the market, many people still haven’t heard of the company behind the product. Therefore, they can’t tell whether or not Vitaae is a legitimate product or whether it’s just another supplement scam. If this sounds like you fit the category of unsure, you can rest easy knowing that Vitaae is 100% legitimate, and here’s why: Vitaae is formulated with clinically proven & patented ingredients: Many of the ingredients inside Vitaae are patented ingredients that are clinically proven to deliver some form of cognitive boost. In fact, all of the ingredients in Vitaae are clinically studied for both safety and effectiveness. Vitaae is manufactured in the United States: Vitaae sources all of its’ products from the United States, and it makes its’ products here too. Vitaae is produced in an FDA-approved lab, which means it is produced under strict, clean manufacturing standards to prevent contamination. Vitaae is 3rd party tested for potency and purity: Before Vitaae is shipped to SANE Labs, it is tested multiple times before, during, and after the manufacturing process to ensure that the safest, highest quality ingredients were included. Likewise, it is tested to ensure no contaminants found their way into the product during the manufacturing process. SANE Labs has a stellar reputation and tremendous history: Many supplement companies come and scam consumers. SANE Labs has been around forever and has an incredible history of delivering quality products. They are arguably one of the most trusted companies in the supplement space and very transparent about all of their products. How to Order Vitaae If you’re ready to enhance your cognitive abilities today, then you need to head to the official website of SANE Labs and get your bottle of Vitaae while supplies last. On the website, you’ll see several purchasing options, with steep discounts given on the multiple bottle purchase: One Bottle: $47 Each Three bottles: $42/bottle - $126 total Six Bottles: $33/bottle - $198 total Best of all, no matter which package you select, you’ll receive an exclusive 365-day money-back guarantee from SANE Labs. If for any reason you don’t see results, aren’t satisfied, or feel you have no use for Vitaae any longer, you can contact SANE Labs and receive a full refund for your entire order – no questions asked. Contacting the SANE Labs customer service desk can be done with a phone call or sending an email, 8 am to 5 pm EST Monday through Friday at: Phone: (347) 979-1735 Email: Service@SANESolution.com Company Address: SANESolution 60 W 2nd Ave #100 Spokane, WA 99201 No other supplement company comes remotely close to offering a guarantee like this, which is just another reason why SANE Labs is one of the supplement industry leaders. Final Thoughts There’s not much more to say about Vitaae. It’s one of the best cognitive enhancers on the market, with proven ingredients backed by actual science. Not to mention it is manufactured and sold by one of the most trusted names in the supplement industry. Bioavailable Folate, Cognizin Citicoline, L-Carnitine, and MicroActive CoQ10 are the key ingredients of Vitaae listed on the official product description page. When used together in the right amounts, these ingredients can result in a number of potential benefits. “All-day cellular energy,” brain cellular synthesis, “increased focus,” improved weight loss, and improved mood are all results associated with the correct use of key ingredients in this formula. We do have reason to believe that this supplement might help consumers to improve overall brain power, brain function, and memory. Please keep in mind that this is certainly no Limitless pill. If you are experiencing serious memory problems, no supplement is going to correct your brain’s trajectory along the path of aging. However, at least some evidence available online suggests that this formula might help people improve cognitive function and memory retention. If you’re someone who feels like you’ve lost your mental edge, need to improve your performance, or want to enhance your focus and productivity, you need to visit the official website of Vitaae and order your bottles of the #1 natural cognitive enhancer today! Official Website - Contact Details: Sane Solution (Vitaae) EMAIL: Service@SANESolution.com PHONE: (347) 979-1735 About MarketingByKevin.com This product review is published by Marketing By Kevin. Marketing By Kevin reviews are researched and formulated by a group of experienced natural health advocates with years of dedication and determination to finding the highest quality health products and wellness programs available. It should be noted that any purchase derived from this resource is done at your own peril. It is recommended to consult with a qualified professional healthcare practitioner before making an order today if there are any additional questions or concerns. Any order finalized from this release’s links are subject to the entire terms and conditions of the official website’s offer. The researched information above does not take any direct or indirect responsibility for its accuracy. Affiliate Disclosure: The links contained in this product review may result in a small commission to Marketing By Kevin if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products. Disclaimer: Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. Product support: Service@SANESolution.com Media Contact: info@marketingbykevin.com

– Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics – – Enrollment continues in second patient cohort of EnACT study of MAT2203 in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data of key second patient cohort anticipated Q3 2021 – – Collaboration with National Institute of Allergy and Infectious Disease (NIAID) to formulate Gilead’s antiviral COVID-19 medication remdesivir has progressed into in vitro studies – – Data from ENHANCE-IT study of LYPDISO™ against Vascepa® support continued development of LYPDISO as a potential best-in-class prescription-only omega-3 with robust EPA-levels; partnership process ongoing – – Management to host conference call today, Monday, March 29th, at 8:00 a.m. ET – BEDMINSTER, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today reported financial results for the fourth quarter and full year ended December 31, 2020, along with a corporate update. “2020 was a year of significant progress and timely execution for Matinas, despite the ongoing global pandemic. The completion of the head-to-head ENHANCE-IT trial of LYPDISO vs. Vascepa® and the results which support the potential for LYPDISO to demonstrate a superior cardioprotective effect to Vascepa®, have positioned us to identify and potentially secure a global partner for the continued development of this promising, next-generation drug,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas. “This process provides us the opportunity, as we move forward, to re-focus our internal expertise and financial resources on our LNC platform delivery technology. We believe that the unique capability of our LNC formulations to mimic enveloped viruses and efficiently deliver small and large molecules intracellularly without causing adverse immune responses or damage to cellular membranes, differentiates our technology from any other available intracellular delivery technology being applied today.” Mr. Jabbour continued, “There are three key areas which highlight tangible progress with the LNC platform. First, DSMB review and cohort progression in the EnACT study of MAT2203 in cryptococcal meningitis is anticipated in the third quarter of 2021 and provides a near-term opportunity to further validate the LNC platform and highlight its ability to facilitate oral bioavailability and then carry molecules effectively across the blood-brain barrier in combating deadly invasive fungal infections. Second, with the support of the Cystic Fibrosis Foundation, we are rapidly advancing our second LNC platform drug, MAT2501 (oral amikacin), into preclinical toxicology and efficacy studies with the ultimate goal of developing the first oral aminoglycoside for the treatment of nontuberculous mycobacterial infections, as well as gram negative bacterial infections. Finally, we continue to make important progress in expanding the utilization of the LNC platform through our collaborations with Genentech and with NIAID in creating an oral formulation of Gilead’s remdesivir. We are also evaluating additional opportunities to expand application of our LNC platform in other innovative areas, such as mRNA and gene therapy. 2021 will be an exciting and potentially transformational year for our Company, and we look forward to continuing to execute on our corporate strategy and keeping investors informed as to our progress.” MAT2203 Program Update (orally bioavailable amphotericin B, with targeted delivery, under development for the treatment and prevention of invasive fungal infections, including cryptococcal meningitis) Data from the Phase 1 portion of the EnACT study were published in the Antimicrobial Agents and Chemotherapy, (ACC), a journal of the American Society of Microbiology, in a manuscript entitled “Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT trial”. In the published manuscript, trial investigators concluded that MAT2203 was well-tolerated when administered in 4-6 divided daily doses without the toxicities commonly seen with IV amphotericin B, with nearly 100% of patients expressing a preference for oral MAT2203 relative to amphotericin B delivered intravenously. In October 2020, the Company announced that the independent DSMB of the EnACT study completed a pre-specified review of the first cohort and unanimously recommended progression to the second cohort. We have recently reached 50 percent of patient enrollment (28/56) in Cohort Two of the EnACT study (Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial); DSMB evaluation of full safety and efficacy data from Cohort Two is anticipated in the third quarter of 2021. As previously reported, the U.S. Food and Drug Administration (FDA) has designated MAT2203 as a Qualified Infectious Disease Product (QIDP) with Fast Track status for four indications, specifically, the prevention of invasive fungal infections due to immunosuppressive therapy, and the treatment of invasive candidiasis, invasive aspergillus and cryptococcal meningitis. In addition, the FDA has granted orphan drug designation to MAT2203 for the treatment of cryptococcosis. If MAT2203 is ultimately approved by the FDA, the seven-year period of marketing exclusivity from orphan designation combined with the additional five years of marketing exclusivity provided by the QIDP designation, provides for a potential total of 12 years of marketing exclusivity. EnACT is a Phase 2 prospective, randomized, open-label, sequential cohort study, financially supported by the National Institutes of Health (NIH), evaluating the safety, tolerability and efficacy of MAT2203 in approximately 140 HIV-infected patients with cryptococcal meningitis. MAT2203 utilizes the Company’s LNC platform delivery technology to orally deliver the traditionally IV-only fungicidal drug, amphotericin B. In total, the trial includes four cohorts of patients, with each cohort increasing the treatment duration of MAT2203 vs. IV amphotericin B. The primary efficacy endpoint includes a measure of reduction in fungal count in the cerebral spinal fluid. A control arm, which includes standard of care IV amphotericin B, is included with each cohort. MAT2501 Program Update (orally bioavailable amikacin, with targeted delivery, under development for the treatment of nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF)) In November 2020, the Company received a commitment for $3.75 million of funding from the Cystic Fibrosis Foundation (CFF) to support preclinical development of MAT2501 toward an indication to treat NTM lung disease, including infections in patients with CF. The Company is progressing development of MAT2501 through preclinical toxicology and efficacy studies in 2021, with the goal of completing a Phase 1 single ascending dose pharmacokinetic study in healthy volunteers by the end of 2021. MAT2501 has been designated as a QIDP and as an Orphan Drug for the treatment of NTM by the FDA. If MAT2501 is ultimately approved by the FDA, the seven-year period of marketing exclusivity from orphan designation combined with the additional five years of marketing exclusivity provided by the QIDP designation, provides for a potential total of 12 years of marketing exclusivity. LNC Platform Update The Company’s feasibility agreement with Genentech, which involves the formulation of up to three different Genentech compounds, was extended for an additional two years in November of 2020. In December 2020, the Company announced a collaboration with the NIAID to evaluate oral formulations of Gilead’s antiviral remdesivir utilizing Matinas’ LNC platform delivery technology. The Company recently prepared and delivered several formulations to NIAID, which will commence planned preclinical studies promptly. LYPDISO™ Program Update (next generation, prescription-only omega-3 fatty acid-based composition under development for treatment of cardiovascular and metabolic conditions, including hypertriglyceridemia) In February 2021, the Company announced topline results from ENHANCE-IT (Pharmacodynamic Effects of a Free-fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a second head-to-head comparative study of LYPDISO vs. Vascepa®. The study assessed LYPDISO’s effectiveness in reducing triglyceride levels and other important lipid markers, as well as characterizing bioavailability and blood levels of eicosapentaenoic acid (EPA) and other omega-3 fatty acids. While the primary endpoint of percent change in triglycerides (TGs) from baseline to end-of-treatment did not meet statistical significance in the pre-specified pharmacodynamic population, analysis of the per protocol population demonstrated statistically significant improvement and superiority of LYPDISO over Vascepa® in reducing TGs, total cholesterol and very-low-density lipoprotein cholesterol. A key secondary endpoint in ENHANCE-IT was the measurement of EPA levels in the blood, as that has become a key surrogate marker in determining cardiovascular risk reduction. In ENHANCE-IT, plasma EPA concentrations were significantly higher with LYPDISO vs. Vascepa® (46% relative percent increase in the change from baseline EPA level vs. Vascepa®), which the Company believes indicates the potential for superior cardioprotection with LYPDISO vs. Vascepa®. The Company believes that the results from ENHANCE-IT suggest potential for LYPDISO as a best-in-class prescription-only omega-3 drug for cardiovascular risk reduction and is pursuing a partnership to continue further development of LYPDISO toward a cardiovascular outcomes indication. Accordingly, the Company no longer plans to pursue an indication for the treatment of severe hypertriglyceridemia. Fourth Quarter and Full Year 2020 Financial Results Cash, cash equivalents and marketable securities at December 31, 2020 were approximately $58.7 million, compared to $27.8 million at December 31, 2019. In January 2020, the Company sold an aggregate of 32.3 million shares of its common stock at a price of $1.55 per share for net proceeds of approximately $46.7 million, after deducting underwriting discounts and commissions and other offering expenses. In July 2020, the Company entered into an At-The-Market Sales Agreement (Sales Agreement) with BTIG, LLC (BTIG), pursuant to which the Company may offer and sell, from time to time, through BTIG, shares of its common stock having an aggregate offering price of up to $50 million, subject to certain limitations on the amount of common stock that may be offered and sold by the Company set forth in the Sales Agreement. As of December 31, 2020, the Company did not sell any shares of its common stock under the Sales Agreement. During January 2021, BTIG sold approximately 3 million shares of the Company’s common stock under the Sales Agreement generating net proceeds to the Company of approximately $5.6 million. Based on current projections, the Company believes that cash on hand, including net proceeds from issuances under the Sales Agreement in January 2021, is sufficient to fund operations into 2024. For the fourth quarter of 2020, net loss attributable to common shareholders was $6.6 million, or a net loss of $0.03 per share (basic and diluted), compared to a net loss attributable to common shareholders of $5.8 million, or a net loss of $0.04 per share (basic and diluted) for the same period in 2019. For the full year of 2020, net loss attributable to common shareholders was $23.2 million, or a net loss per share of $0.12 (basic and diluted), compared to a net loss attributable to common shareholders of $18.3 million, or a net loss per share of $0.13 (basic and diluted) for the full year of 2019. The increase for both periods was due primarily to an increase in operating expenses, as more fully described below. Research and development (R&D) expenses for the fourth quarter of 2020 were $3.5 million, compared to $3.4 million for the same period in 2019. For the full year of 2020, R&D expenses were $14.4 million, compared to $11.2 million for the full year of 2019. The increase for full year 2020 was due primarily to higher preclinical and clinical development expenses and employee compensation related to the development of LYPDISO, MAT2203 and MAT2501. General and administrative (G&A) expenses for the fourth quarter of 2020 were $3.0 million, compared to $2.3 million in the same period in 2019. For the full year of 2020, G&A expenses were $10.0 million, compared to $7.8 million for the full year of 2019. The increase was due primarily to employee related expenses and professional fees. *Vascepa® is a registered trademark of the Amarin group of companies. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results on Monday, March 29, 2021, at 8:00 a.m. ET. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13716272. The live webcast will be accessible on the Investors section of Matinas’ website, , and archived for 90 days About Matinas BioPharma Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform. Company leadership has a deep history and knowledge of drug development and is supported by a world-class team of scientific advisors. Matinas is developing a portfolio of products based upon its proprietary LNC drug delivery platform, which can solve complex challenges relating to the safe and effective intracellular delivery of both small and larger, more complex molecules. MAT2203 is an oral, LNC formulation of the well-known, but highly toxic, antifungal medicine amphotericin B, primarily used to treat serious invasive fungal infections. MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis. EnACT is currently enrolling patients in its second cohort, with the next DSMB evaluation of safety and efficacy data anticipated to occur in the third quarter of 2021. MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic medicine amikacin, primarily used to treat chronic and acute bacterial infections. The Company has been awarded up to $3.75 million from the Cystic Fibrosis Foundation (CFF) to support development of MAT2501 toward an indication to treat nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF). LYPDISO™, the Company’s product candidate intended for the treatment of cardiovascular and metabolic conditions, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, recently announced data from the ENHANCE-IT study, a head-to-head crossover study evaluating LYPDISO vs. Vascepa in patients with elevated triglycerides. Data demonstrating superior levels of eicosapentaenoic acid (EPA) in the blood with LYPDISO support the potential superior cardioprotective effect of LYPDISO vs. Vascepa. The Company has initiated a process to identity and secure a potential partner to continue development of LYPDISO toward a cardiovascular outcomes indication. Forward Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the LNC platform delivery technology, the Company’s strategic focus and the future development of its product candidates, including MAT2203, MAT2501 and LYPDISO, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use. Matinas BioPharma Holdings Inc. Consolidated Balance Sheets Investor and Media Contacts Peter Vozzo Westwicke/ICR 443-213-0505 peter.vozzo@westwicke.com Source: Matinas BioPharma Holdings, Inc.